Intuitive Surgical: Leader in Robotic Surgery Market
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 19 2026
0mins
Source: Fool
- Market Dominance: Intuitive Surgical's da Vinci Xi system is the most widely used multiport robotic surgery system globally, utilized in over 3 million surgeries last year; despite a more than 17% drop in stock price this year, its market share remains robust.
- Training Barrier: Most surgeons trained on the da Vinci platform during residency face significant retraining to switch to competitors' systems, making hospitals reluctant to disrupt established workflows in high-stakes surgery, thereby solidifying Intuitive's market position.
- Economic Cycle Advantage: With over 12,100 systems installed globally, 81% of Intuitive's revenue comes from recurring sales of instruments, accessories, and services, making it unlikely for hospitals to replace existing da Vinci systems even if they purchase a competitor's robot due to substantial capital already invested.
- Innovation Drive: The company invested $1.3 billion in R&D last year, with the rollout of the da Vinci 5 expected to be a major catalyst for 2026; its force feedback technology can reduce applied force by up to 43%, improving surgical outcomes and enhancing competitive strength.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ISRG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ISRG
Wall Street analysts forecast ISRG stock price to rise
20 Analyst Rating
16 Buy
4 Hold
0 Sell
Strong Buy
Current: 418.610
Low
575.00
Averages
637.32
High
740.00
Current: 418.610
Low
575.00
Averages
637.32
High
740.00
About ISRG
Intuitive Surgical, Inc. develops, manufactures, and markets da Vinci surgical systems and the Ion endoluminal system. The Company specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Three Stocks to Hold for the Long Term
- Berkshire Hathaway's Stability: With a market cap of $1.1 trillion, Berkshire Hathaway's beta of 0.62 indicates relative stability during market downturns, making it a reliable long-term hold for steady returns.
- Intuitive Surgical's Growth Potential: Intuitive Surgical, valued at $151 billion, saw a 17% year-over-year increase in procedures and a 23% rise in revenue, with its service contracts and accessory sales providing sustainable income and a promising growth outlook.
- Nvidia's Market Leadership: Nvidia's market cap of $5 trillion and Q1 revenue of $81.6 billion, up 85% year-over-year, alongside a 92% increase in data center revenue, highlight strong demand in AI processing, positioning it for significant future growth.
- Diversification of Investment Portfolio: These three companies dominate their respective sectors in insurance, healthcare, and semiconductors, offering diverse investment options that can maintain stable long-term growth across varying market conditions.
See More
Three Quality Stocks for Long-Term Investment
- Buffett's Confidence: Berkshire Hathaway's CEO Warren Buffett has demonstrated strong management over the years, with a beta of 0.62 indicating that its stock price fluctuates only 62% as much as the market during volatility, showcasing its resilience.
- Leader in Surgical Systems: Intuitive Surgical boasts a market value of $151 billion with over 12,000 robotic surgical systems installed globally, and in Q1, it reported a 17% year-over-year increase in procedures and a 23% rise in revenue, highlighting its robust growth potential and stable service contract income.
- Growth Engine in Data Centers: Nvidia achieved $81.6 billion in revenue in Q1, an 85% year-over-year increase, with data center revenue reaching $75.2 billion, up 92%, positioning it favorably in the AI processing market despite a 25% stock price decline over the past year.
- Valuation Opportunity: Intuitive Surgical's forward P/E ratio stands at 44, below the five-year average of 55, indicating that its current stock price is relatively reasonable, making it an attractive option for investors looking to capitalize on future growth opportunities.
See More
Medtronic's Hugo Robotic Surgery Platform Approved
- FDA Approval Milestone: Medtronic's Hugo robotic surgery platform received FDA approval in December 2025 for urologic procedures, marking its official entry into the robotic surgery market, with approximately 230,000 related surgeries performed annually in the U.S., indicating significant market potential.
- Competitive Pressure: Despite the approval, Medtronic faces fierce competition from Intuitive Surgical, which has dominated the market since 1999 and currently has 11,395 da Vinci systems installed globally, creating a strong user base and market barriers.
- Growth Potential: The Hugo system has already been used in tens of thousands of procedures across 35 countries, with Medtronic's CEO noting that procedure volumes are growing two to three times faster than the market, suggesting promising future growth, especially as robotic surgeries currently account for only 5% of global surgeries.
- Financial Strength Comparison: Medtronic is projected to generate $38.8 billion in total revenue this fiscal year, significantly surpassing Intuitive Surgical's $11.7 billion, indicating that while it may not lead in robotic surgery, its diversified healthcare portfolio and strong financial foundation allow for sustained growth in the market.
See More
Medtronic's Hugo Surgery Platform Approved in U.S.
- FDA Approval Milestone: Medtronic's Hugo robotic-assisted surgery platform received FDA approval for urologic procedures in December 2025, marking the company's official entry into the robotic surgery market, despite facing strong competition from Intuitive Surgical.
- Significant Market Potential: With approximately 230,000 related surgeries performed annually in the U.S., the approval opens up a substantial market opportunity for Medtronic, as the robotic surgery market is projected to grow from $13.8 billion last year to $63.7 billion by 2035.
- Accelerated Growth Rate: Medtronic's CEO disclosed during the Q4 2026 earnings call that procedure volumes for Hugo are growing two to three times faster than the market, indicating strong growth potential despite starting from a small base, which could lead to increased market share in the future.
- Global Deployment Advantage: The Hugo system is already in use in over 35 countries, with hospitals having performed tens of thousands of procedures; while it may not surpass Intuitive Surgical's market position, Medtronic's diversified healthcare product portfolio provides a solid foundation to capture opportunities in the rapidly growing robotic surgery market.
See More
Three Undervalued Growth Stocks to Consider
- Robotic Surgery Market Outlook: Intuitive Surgical's stock has fallen 27% in 2026, and while it leads the robotic-assisted surgery market, its high valuation has pressured the stock, currently trading at a forward P/E of about 40, with significant growth potential as the global surgical robot market is projected to reach $18.5 billion by 2033.
- Telecom Industry Resilience: T-Mobile's stock is down 13%, yet it reported an 11% revenue growth in Q1 2026 despite fears of competition from SpaceX, with a forward P/E of 17, below the S&P 500 average of 22, indicating strong competitive positioning in the telecom sector.
- Credit Card Industry Leader: Mastercard's Q1 2026 revenue reached $8.4 billion, up 16% year-over-year, with profits surging 18% to $3.9 billion; despite concerns over potential caps on credit card interest rates, its business remains robust, trading at a forward P/E of 24, lower than its historical average, making it a solid investment choice.
- Investment Opportunity Analysis: Although Intuitive Surgical was not recommended by Motley Fool Stock Advisor, its strong demand in the healthcare sector and future growth potential make it a stock to watch, especially given its current undervaluation, presenting a compelling long-term investment opportunity.
See More
Three Quality Growth Stocks Hit New Lows
- Intuitive Surgical Performance: Intuitive Surgical's stock has fallen 27% in 2026, and despite being a leader in the robotic-assisted surgery market, its high valuation has pressured the stock, currently trading at a P/E of about 50 and a forward P/E of 40, indicating potential for long-term investment.
- Market Growth Potential: The global surgical robot market was valued at $6.6 billion in 2022 and is projected to grow to $18.5 billion by 2033, suggesting that while the market is still small, the growth prospects could yield significant returns for investors.
- T-Mobile Competitive Edge: T-Mobile's stock has dropped 13% this year, but despite intense competition and market concerns, it reported an impressive revenue growth of around 11% in Q1 2026, demonstrating strong market adaptability and customer satisfaction.
- Mastercard Financial Performance: Mastercard's revenue reached $8.4 billion in Q1 2026, up 16% year-over-year, with profits surging 18% to $3.9 billion, showcasing robust growth potential despite concerns over interest rate caps, making it a compelling investment opportunity.
See More
Three Stocks to Hold for the Long Term
- Berkshire Hathaway's Stability: With a market cap of $1.1 trillion, Berkshire Hathaway's beta of 0.62 indicates relative stability during market downturns, making it a reliable long-term hold for steady returns.
- Intuitive Surgical's Growth Potential: Intuitive Surgical, valued at $151 billion, saw a 17% year-over-year increase in procedures and a 23% rise in revenue, with its service contracts and accessory sales providing sustainable income and a promising growth outlook.
- Nvidia's Market Leadership: Nvidia's market cap of $5 trillion and Q1 revenue of $81.6 billion, up 85% year-over-year, alongside a 92% increase in data center revenue, highlight strong demand in AI processing, positioning it for significant future growth.
- Diversification of Investment Portfolio: These three companies dominate their respective sectors in insurance, healthcare, and semiconductors, offering diverse investment options that can maintain stable long-term growth across varying market conditions.
See More
Three Quality Stocks for Long-Term Investment
- Buffett's Confidence: Berkshire Hathaway's CEO Warren Buffett has demonstrated strong management over the years, with a beta of 0.62 indicating that its stock price fluctuates only 62% as much as the market during volatility, showcasing its resilience.
- Leader in Surgical Systems: Intuitive Surgical boasts a market value of $151 billion with over 12,000 robotic surgical systems installed globally, and in Q1, it reported a 17% year-over-year increase in procedures and a 23% rise in revenue, highlighting its robust growth potential and stable service contract income.
- Growth Engine in Data Centers: Nvidia achieved $81.6 billion in revenue in Q1, an 85% year-over-year increase, with data center revenue reaching $75.2 billion, up 92%, positioning it favorably in the AI processing market despite a 25% stock price decline over the past year.
- Valuation Opportunity: Intuitive Surgical's forward P/E ratio stands at 44, below the five-year average of 55, indicating that its current stock price is relatively reasonable, making it an attractive option for investors looking to capitalize on future growth opportunities.
See More
Medtronic's Hugo Robotic Surgery Platform Approved
- FDA Approval Milestone: Medtronic's Hugo robotic surgery platform received FDA approval in December 2025 for urologic procedures, marking its official entry into the robotic surgery market, with approximately 230,000 related surgeries performed annually in the U.S., indicating significant market potential.
- Competitive Pressure: Despite the approval, Medtronic faces fierce competition from Intuitive Surgical, which has dominated the market since 1999 and currently has 11,395 da Vinci systems installed globally, creating a strong user base and market barriers.
- Growth Potential: The Hugo system has already been used in tens of thousands of procedures across 35 countries, with Medtronic's CEO noting that procedure volumes are growing two to three times faster than the market, suggesting promising future growth, especially as robotic surgeries currently account for only 5% of global surgeries.
- Financial Strength Comparison: Medtronic is projected to generate $38.8 billion in total revenue this fiscal year, significantly surpassing Intuitive Surgical's $11.7 billion, indicating that while it may not lead in robotic surgery, its diversified healthcare portfolio and strong financial foundation allow for sustained growth in the market.
See More
Medtronic's Hugo Surgery Platform Approved in U.S.
- FDA Approval Milestone: Medtronic's Hugo robotic-assisted surgery platform received FDA approval for urologic procedures in December 2025, marking the company's official entry into the robotic surgery market, despite facing strong competition from Intuitive Surgical.
- Significant Market Potential: With approximately 230,000 related surgeries performed annually in the U.S., the approval opens up a substantial market opportunity for Medtronic, as the robotic surgery market is projected to grow from $13.8 billion last year to $63.7 billion by 2035.
- Accelerated Growth Rate: Medtronic's CEO disclosed during the Q4 2026 earnings call that procedure volumes for Hugo are growing two to three times faster than the market, indicating strong growth potential despite starting from a small base, which could lead to increased market share in the future.
- Global Deployment Advantage: The Hugo system is already in use in over 35 countries, with hospitals having performed tens of thousands of procedures; while it may not surpass Intuitive Surgical's market position, Medtronic's diversified healthcare product portfolio provides a solid foundation to capture opportunities in the rapidly growing robotic surgery market.
See More
Three Undervalued Growth Stocks to Consider
- Robotic Surgery Market Outlook: Intuitive Surgical's stock has fallen 27% in 2026, and while it leads the robotic-assisted surgery market, its high valuation has pressured the stock, currently trading at a forward P/E of about 40, with significant growth potential as the global surgical robot market is projected to reach $18.5 billion by 2033.
- Telecom Industry Resilience: T-Mobile's stock is down 13%, yet it reported an 11% revenue growth in Q1 2026 despite fears of competition from SpaceX, with a forward P/E of 17, below the S&P 500 average of 22, indicating strong competitive positioning in the telecom sector.
- Credit Card Industry Leader: Mastercard's Q1 2026 revenue reached $8.4 billion, up 16% year-over-year, with profits surging 18% to $3.9 billion; despite concerns over potential caps on credit card interest rates, its business remains robust, trading at a forward P/E of 24, lower than its historical average, making it a solid investment choice.
- Investment Opportunity Analysis: Although Intuitive Surgical was not recommended by Motley Fool Stock Advisor, its strong demand in the healthcare sector and future growth potential make it a stock to watch, especially given its current undervaluation, presenting a compelling long-term investment opportunity.
See More
Three Quality Growth Stocks Hit New Lows
- Intuitive Surgical Performance: Intuitive Surgical's stock has fallen 27% in 2026, and despite being a leader in the robotic-assisted surgery market, its high valuation has pressured the stock, currently trading at a P/E of about 50 and a forward P/E of 40, indicating potential for long-term investment.
- Market Growth Potential: The global surgical robot market was valued at $6.6 billion in 2022 and is projected to grow to $18.5 billion by 2033, suggesting that while the market is still small, the growth prospects could yield significant returns for investors.
- T-Mobile Competitive Edge: T-Mobile's stock has dropped 13% this year, but despite intense competition and market concerns, it reported an impressive revenue growth of around 11% in Q1 2026, demonstrating strong market adaptability and customer satisfaction.
- Mastercard Financial Performance: Mastercard's revenue reached $8.4 billion in Q1 2026, up 16% year-over-year, with profits surging 18% to $3.9 billion, showcasing robust growth potential despite concerns over interest rate caps, making it a compelling investment opportunity.
See More
